High Yield Revival: 3 Cash-Rich Dividend Payers on Sale Market rotation is driving investors toward dependable income; these high-yield dividend stocks offer strong cash flow and defensive positioning MarketBeat · Feb 20
S&P 500, MidCap 400, and SmallCap 600 Welcome New Members as Indexes Rebalance for 2026 The S&P 500’s latest rebalance reveals how the index quietly upgrades itself by promoting winners like Carvana and CRH and removing underperformers through a process that more closely resembles disciplined active management than passive investing. Barchart · Jan 7
Top 3 Health Care Stocks That May Rocket Higher In December The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. Benzinga · Dec 3, 2025
Missed Opt-Out Deadline Could Cost Investors Millions In Perrigo Fraud Suit Perrigo plc (NYSE:PRGO), the largest maker of over-the-counter healthcare products, is at the center of a years-long legal dispute stemming from its rejection of a takeover bid and subsequent fallout that cost shareholders billions. Benzinga · Aug 13, 2025
These 3 Dividend Stocks Combine Strong Yields With Upside These three high-yield dividend stocks are well-positioned to deliver a strong return, making them attractive to both income and growth-oriented investors MarketBeat · Jun 20, 2025
3 Dividend Stocks to Buy Now With Yields of About 4% or More Three dividend stocks, Kimco Realty, Perrigo Company, and Permian Resources, are highlighted as attractive options for investors seeking steady income, with yields of 3.9% or more and strong fundamentals across the real estate, healthcare, and energy sectors. Barchart · Nov 26, 2024
3 Lucrative Pharma Stocks to Diversify Your Investments The pharma industry’s resilience and long-term prospects are driven by rising healthcare demand, an enhanced focus on precision medicines, and technological advancements. Hence, let’s take a look at pharma stocks Perrigo Company (PRGO), Amneal Pharmaceuticals (AMRX), and Supernus Pharmaceuticals (SUPN), which could diversify your investments. Read on…. StockNews.com · Apr 9, 2024
3 Pharma Stocks to Consider for March Gains The pharmaceutical industry is experiencing rapid growth due to rising healthcare spending, an aging population, several technological advancements, and a favorable regulatory environment. Thus, it could be ideal to invest in quality pharma stocks Perrigo (PRGO), OptiNose (OPTN), and Teva Pharmaceutical (TEVA) for solid gains. Keep reading…. StockNews.com · Feb 29, 2024
Bolster Your Portfolio with These 3 Pharma Stock Buys The pharmaceutical industry is booming because of the increasing need for quality healthcare and high-quality medicines, the fast-growing elderly population, and the uptick in chronic illnesses. To capitalize on the industry’s growth prospects, investors could consider buying fundamentally strong pharma stocks Perrigo Company (PRGO), ACADIA Pharmaceuticals (ACAD), and Pacira BioSciences… StockNews.com · Feb 15, 2024
Relay Therapeutics (RLAY) vs. Perrigo Company (PRGO): Which Pharma Stock Holds Better Upside Potential? The pharmaceutical industry’s prospects look bright, fueled by a rapidly aging population, the rising prevalence of chronic diseases, consistent R&D efforts backed by government funding, and digital transformation. Pharma stocks Relay Therapeutics (RLAY) and Perrigo Company (PRGO) should benefit from the industry tailwinds. But let’s find out which stock holds… StockNews.com · Sep 8, 2023
Is Perrigo a Buy After Reporting Q1 Earnings? The shares of leading baby formula maker Perrigo Company (PRGO) have been soaring in price of late amid a nationwide baby formula shortage. So, because the crisis is expected to continue through the coming months, will PRGO be able to maintain this momentum in the near term? Read more to… StockNews.com · May 20, 2022
Perrigo Shares Pop On Raised FY22 Guidance Surpassing Consensus Estimates Perrigo Company plc's (NYSE: PRGO) Q1 FY22 sales increased 6.4% Y/Y to $1.07 billion, almost in line with the consensus of $1.1 billion. The growth was led by strong consumer demand, particularly for cough/cold products globally and infant formula in the U.S. after competitor recall. Adjusted EPS decreased 34% to $0.33, as higher sales… Benzinga · May 11, 2022
Perrigo Clocks 5% Sales Growth In Q4, Bottom-Line Surpass Expectation Perrigo Company plc (NYSE: PRGO) Benzinga · Mar 1, 2022
Perrigo: Q4 Earnings Insights Perrigo (NYSE:PRGO) reported its Q4 earnings results on Tuesday, March 1, 2022 at 06:30 AM. Here's what investors need to know about the announcement. Benzinga · Mar 1, 2022